AMC Amur Minerals Corporation

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA, THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN AMUR MINERALS CORPORATION OR ANY OTHER ENTITY IN ANY JURISDICTION.

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

29 May 2024

AMUR MINERALS CORPORATION

(AIM: AMC)

Result of AGM and GM

Amur Minerals Corporation ("Amur" or the "Company") is pleased to announce that, at its Annual General Meeting and General Meeting held earlier today, all of the resolutions were duly passed, including the acquisition of Extruded Pharmaceuticals Limited.

The total number of votes received on the resolutions put to the AGM and GM were as follows:

Annual General Meeting

General Meeting

Accordingly, the following proposals will become unconditional in all respects:

-       On Admission, the Acquisition by the Company of the entire issued and to be issued share capital of Extruded Pharmaceuticals Limited for an aggregate consideration of £5.5 million, to be satisfied by the issue of 23,939,986 New Ordinary Shares;

-       The Share Consolidation at a ratio of 1:160 whereby holders of Existing Ordinary Shares will receive 1 New Ordinary Share for every 160 Existing Ordinary Shares held;

-       The Company's name changed to CRISM Therapeutics Corporation; and

-       The resignation of each of Robert Schafer, Robin Young, Thomas Bowens and Paul Gazzard, and the appointments of Dr Nermeen Varawalla as Independent Non-Executive Chair, Andrew Webb as Chief Executive Officer, Dr Christopher McConville as Chief Scientific Officer and Gerald Beaney as Independent Non-Executive Director.

Admission, Settlement and Dealings

Application has been made to the London Stock Exchange for the 32,678,150 New Ordinary Shares to be admitted to trading on AIM. It is expected that Admission will become effective and that dealings in the New Ordinary Shares will commence on AIM at 8.00 a.m. on 31 May 2024. Trading in the Company's Existing Ordinary Shares will remain suspended until such time.

The New Ordinary Shares will be in registered form and will be capable of being held in either certificated or uncertificated form (i.e. in CREST). Accordingly, following Admission, settlement of transactions in the New Ordinary Shares may take place within the CREST system if a Shareholder so wishes. In respect of Shareholders who will receive New Ordinary Shares in uncertificated form, New Ordinary Shares will be credited to their CREST stock accounts on or around 31 May 2024. Shareholders who wish to receive and retain share certificates are able to do so and share certificates representing the New Ordinary Shares to be issued pursuant to the Proposals are expected to be despatched by post to such Shareholders by 14 June 2024.

Defined terms used in this announcement carry the same meanings as those ascribed to them in the Company's Admission Document published on 13 May 2024, unless the context requires otherwise.

Enquiries: